CancerIQ

CancerIQ

Hospitals and Health Care

Chicago, Illinois 8,064 followers

We connect a broader population of patients and providers to innovations in prevention, early detection, and treatment.

About us

About Us CancerIQ helps providers use genetic information to predict, pre-empt, and prevent disease - starting with cancer. By making is easier to identify patients at risk, offer a genetic evaluation at point of care, and design a tailored cancer prevention plan - we can help healthcare systems get ahead of this costly and emotionally devastating disease. Why Work with Us? We have quietly built a market-leading product that patients, providers, and healthcare executives all love. With new funding and new strategic partners, we're on pace for rapid growth. We're a team of clever, scrappy, and mission-driven individuals making a huge impact in cancer prevention - so if you're passionate about healthcare - join our team.

Website
http://www.canceriq.com
Industry
Hospitals and Health Care
Company size
11-50 employees
Headquarters
Chicago, Illinois
Type
Privately Held
Founded
2013
Specialties
Software, Healthcare IT, Big Data Analytics, Oncology, and Precision Medicine

Locations

Employees at CancerIQ

Updates

  • View organization page for CancerIQ, graphic

    8,064 followers

    Join us on July 18th 3:30PM ET/ 12:30PM PT to discover how Nebraska Medicine transformed their approach to cancer screening by implementing CancerIQ’s newest digital tools for targeted, campaign-based patient outreach. Easy-to-launch marketing strategies can help your organization capture high-risk patients and navigate them to hyper-personalized care prior to a diagnosis. Rachael Schmidt, APRN, Cancer Survivorship & Cancer Risk Prevention Program Director, and Assistant Director of Health Promotion & Screening, joins the CancerIQ team to discuss how she scaled her program, leading to significant increases in scheduled low-dose CT scans and preventive services. This successful model is now being replicated for colon cancer screening in GI specialties and employee wellness programs. Register below via LinkedIn or Visit: https://lnkd.in/e_Zt5w7C

    This content isn’t available here

    Access this content and more in the LinkedIn app

  • View organization page for CancerIQ, graphic

    8,064 followers

    Up next at the World Conference Forum 2024 Social Determinants of Health & Health Equity Forum at 4:15PM CT, Feyi Ayodele will take the stage for her session, "A Population Health Approach to Equitable Cancer Prevention and Early Detection." If you're a population health leader responsible for driving significant change but facing budget constraints, this session is for you! Feyi will be addressing the urgent need for health systems to improve risk stratification for tailored cancer prevention and detection. Join us to discover how CancerIQ democratizes access to cancer risk assessment by increasing compliance with cancer screening across diverse populations, proving that culturally tailored patient education drives better health outcomes. #AheadOfCancer #PrecisionPrevention

    2024 Social Determinants of Health & Health Equity Forum

    2024 Social Determinants of Health & Health Equity Forum

    wcforum.com

  • CancerIQ reposted this

    View profile for Feyi Ayodele, graphic

    Founder and CEO at Cancer IQ, Inc.

    On Juneteenth, I took a moment to commemorate a day that has made so much possible for me. I unplugged. I celebrated with friends. I enjoyed the perfect summer weather by the lake in Chicago. I forgot to post. Although we have been free from the burden of slavery for nearly 200 years, I am deeply grateful for the choices people continue to make that shape my journey. I am thankful for my employees who choose to work for a Black woman with a big vision. I appreciate my investors who chose to invest in me, despite less than 1% of venture capital going to people who look like me. I am grateful for my customers who choose to do business with me and uphold their diversity supplier goals. And I am especially thankful for the hundreds of thousands of patients who benefit from our technology, which would not be possible without the end of slavery. Juneteenth is also a day for learning and reflection, and I want to share what drives me at CancerIQ . Despite many advances in oncology, too many people of color continue to die from cancer. African American women are 40% more likely to die of breast cancer than white women, and we are often diagnosed with more aggressive, harder-to-treat diseases at younger ages. The breast cancer death rate for Black women under 50 is twice that of white women. Simply put, when we’re diagnosed with cancer, we don’t win. It’s time for a different approach. Equitable cancer care begins when we recognize that every patient shouldn’t be treated the same because every patient’s risk isn’t the same. Full stop. That’s why I’m proud to say, in the spirit of Juneteenth, that we’re doing something dramatically different at CancerIQ. We are bringing cancer risk assessment out of the clinic to meet patients where they are and to maximize the reach of the genetics workforce. We are producing culturally tailored patient education to promote positive health behaviors. We are sensitive to the fact that “who communicates matters,” working with community health workers, and providing navigation services to populations who really can’t afford to get cancer. Stay tuned for more updates on the progress we're making to end cancer as we know it, for everyone.

    • No alternative text description for this image
  • CancerIQ reposted this

    View profile for Feyi Ayodele, graphic

    Founder and CEO at Cancer IQ, Inc.

    This weekend at American Society of Clinical Oncology (ASCO), American Cancer Society CEO Karen Knudsen MBA PhD issued an important call to action: “Success looks like ending cancer as we know it — for everyone.” Her message was loud and clear: To accelerate progress against cancer, we must consider health equity in every program, solution and intervention. And the time to start is now. At CancerIQ, we could not agree more. Democratizing access to precision health has been in our DNA since the very beginning. Hearing ACS call attention to health equity at ASCO — on National Cancer Survivors Day no less — was a powerful reminder that we are not alone. From the drug companies developing new therapies to the advocacy groups amplifying patient needs to the providers engaging patients in genetic risk assessment and early detection, so many have committed their lives to helping others survive cancer. It was inspiring to be in the same room as so many others working to ensure everyone has the chance to be a survivor. Let’s continue that work, together. #ASCO #NationalCancerSurvivorsDay #NationalCancerSurvivorsMonth #AheadOfCancer

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +4
  • View organization page for CancerIQ, graphic

    8,064 followers

    In the realm of cancer prevention and early detection, healthcare providers continually seek innovative ways to engage with and educate their communities. Beyond the traditional clinic setting, there lies a vast opportunity to connect with individuals who might not be aware of their cancer risk or the preventive measures they can take. CancerIQ's software comes with a full suite of services, including wraparound campaigns that are designed to engage specific populations for risk assesment through a variety of channels, including community events, social media, and direct patient outreach. Learn more: https://bit.ly/3KfHf8f #precisionprevention #aheadofcancer #campaignbasedriskassessment

    Harnessing Digital Campaigns to Scale Cancer Risk Assessment

    Harnessing Digital Campaigns to Scale Cancer Risk Assessment

    blog.canceriq.com

  • View organization page for CancerIQ, graphic

    8,064 followers

    CancerIQ is proud to announce that its co-founder and Chief Scientific Officer Dr. Olufunmilayo (Funmi) Olopade was awarded the 2024 Ellis Island Medal of Honor for her achievements in the field of cancer genetics and genomics. The Ellis Island Medal of Honor, one of the most prestigious awards in the country, recognizes Americans of immigrant descent who have made significant contributions to society. "I am really proud to work on a problem that is solvable. It is no longer acceptable to describe cancer disparities when we can use science and technology to save more lives," said Dr. Olopade. Her latest research, a watershed moment for population diversity in breast cancer genetics research, is the largest genome-wide association study (GWAS) of breast cancer in women of African descent conducted to date and identifies new genetic variants that have been shown to markedly reduce disparities in risk assessment models. Findings from this study were recently published by a team of scientists, including Dr. Olopade, in the peer-reviewed journal Nature Genetics. #precisionprevention #aheadofcancer

    CancerIQ Co-founder Receives Medal of Honor for Achievements in Breast Cancer Prevention and Early Detection

    CancerIQ Co-founder Receives Medal of Honor for Achievements in Breast Cancer Prevention and Early Detection

    prweb.com

  • CancerIQ reposted this

    View profile for Jeffrey Weitzel, graphic

    Precision Prevention, University of Kansas Comprehensive Cancer Center

    It was a pleasure to be back in Chicago for the 12th Annual International Clinical Cancer Genomics Conference, with local hosting by UChicago Medicine. Ever since I helped organize the first "bootcamp" in the series at City of Hope, this forum has always served as a cornerstone for learning about the latest research, technologies and interventions advancing the field of cancer genetics and genomics.   That’s why I was particularly excited to help announce the launch of the VALUE in Cancer Risk Programs Study at this year’s meeting alongside Feyi Ayodele. The VALUE study seeks to answer what I believe is one of the big questions holding back community-level precision health programs, and that is: what is the ROI of risk assessment program implementation for health systems?   Understanding the net financial benefit of cancer risk programs is especially salient given the economic challenges health systems face today. It is our hope that demonstrating the opportunity in digitally enabled cancer risk programs will translate to more widespread adoption of precision cancer prevention, early detection and treatment.    For this research effort, I will be working in partnership with CancerIQ as a scientific advisor for a project to document the downstream revenue of digital interventions for genetically informed cancer care. We are currently seeking health systems to participate — so if would like to learn more or join the study, let’s connect – shoot me a message and I’ll put you in touch with the CIQ team.

    View organization page for CancerIQ, graphic

    8,064 followers

    CancerIQ announces it is seeking health systems to participate in the newly launched, large-scale research effort that will document the downstream revenue of digital interventions for genetically informed cancer prevention, early detection and treatment. The "Validating Applications for Long-term Utility and Enhanced ROI" (VALUE) in Cancer Risk Programs Study aims to bring together health systems from across the country to advance understanding of the system-level financial value of genetics and genomics. Limited data exists on the net financial benefit of digitally enabled cancer risk programs to the healthcare system, largely due to the challenges of measuring downstream revenue and cost savings from disease prevention, improved treatment efficacy and reduced hospitalizations, among other factors. Measuring the ROI of genetics programs is crucial to help allocate resources efficiently, scale clinical impact and optimize technology investments. https://bit.ly/3Q9H4yz

    CancerIQ Launches Research Initiative to Quantify Downstream Value of Digitally Enabled Cancer Risk Programs

    CancerIQ Launches Research Initiative to Quantify Downstream Value of Digitally Enabled Cancer Risk Programs

    prweb.com

  • View organization page for CancerIQ, graphic

    8,064 followers

    The path to implementing comprehensive cancer screening is often fraught with challenges. Common objections like "I don't have time," "I already have too much to do," or "I don't know where to start" can hinder healthcare providers from taking proactive steps. However, digital health tools can address these concerns by streamlining the screening process, offering clinical decision support, and providing educational resources that make starting easier and more efficient. Cancer risk assessment and precision prevention are particularly crucial when considering hereditary cancers, which show themselves through personal and family histories of cancer. The excuses against screening - from doubts about clinical benefit to feelings of unpreparedness in facing potential hereditary risks - must be countered with robust digital strategies that facilitate early detection and intervention. #precisionprevention #aheadofcancer Read more ⬇️

    Meeting Patients Where They Are: Patient-Initiated Cancer Risk Assessment Screenings

    Meeting Patients Where They Are: Patient-Initiated Cancer Risk Assessment Screenings

    blog.canceriq.com

  • View organization page for CancerIQ, graphic

    8,064 followers

    CancerIQ is honored to announce that we have been recognized by Newsweek and Statista as one of the World's Best Digital Health Companies in 2024! This inaugural ranking aims to pinpoint the services and technologies driving real transformation in healthcare. To compile the list, Newsweek and Statista rigorously evaluated over 3,000 companies. "From day one, the team at CancerIQ has worked relentlessly to push the boundaries of cancer care by helping clinicians use genetic information to detect cancer earlier or prevent it altogether – at scale. Being recognized as one of the best digital health companies by Newsweek is yet another validation that our efforts are making an impact," said Feyi Ayodele, founder and CEO of CancerIQ. #aheadofcancer #precisionprevention

    Newsweek Names CancerIQ One of the World's Best Digital Health Companies

    Newsweek Names CancerIQ One of the World's Best Digital Health Companies

    prweb.com

  • View organization page for CancerIQ, graphic

    8,064 followers

    Breaking Breast Imaging News Alert: The U.S. Preventive Services Task Force (USPSTF) has updated its breast cancer screening guidelines. Now, women at average risk are advised to begin biennial mammography screenings at age 40, instead of the previous starting age of 50. However, an accompanying editorial in JAMA OncologyWendie Berg, MD, PhD, of the University of Pittsburgh School of Medicine, pointed out that USPSTF guidelines do not apply to women at high risk for breast cancer, and noted that regular risk assessment should commence at age 25 years to identify the high-risk who should start annual MRI screening. https://lnkd.in/eEmu4BNu

    USPSTF Finalizes New Breast Cancer Screening Recommendations

    USPSTF Finalizes New Breast Cancer Screening Recommendations

    medpagetoday.com

Similar pages

Browse jobs

Funding

CancerIQ 7 total rounds

Last Round

Convertible note
See more info on crunchbase